Nebacumab

Nebacumab is a human monoclonal antibody developed for the treatment of sepsis.^[1] It has been withdrawn in 1993 because it failed to reduce mortality in clinical trials.^[2]

References

↑ Derkx, B.; Wittes, J.; McCloskey, R. (1999). "Randomized, Placebo‐Controlled Trial of HA‐1A, a Human Monoclonal Antibody to Endotoxin, in Children with Meningococcal Septic Shock". Clinical Infectious Diseases 28 (4): 770–726. doi:10.1086/515184. PMID 10825037.
↑ WHO: Consolidated List of Products

Monoclonal antibodies for infectious disease and toxins

Fungal ("-fung-")

Human ("-fungu-")	Efungumab

Viral ("-vi(r)-")

Human ("-viru-")	Exbivirumab Foravirumab Libivirumab Rafivirumab Regavirumab Sevirumab Tuvirumab

Humanized ("-vizu-")	Felvizumab Motavizumab Palivizumab Suvizumab

Bacterial ("-ba(c)-")

Human ("-bacu-")	Nebacumab Panobacumab Raxibacumab

Mouse ("-baco-")	Edobacomab

Chimeric ("-baxi-")	Pagibaximab

Humanized ("-bazu-")	Tefibazumab^†

Toxin ("-tox(a)-")

Immune sera and immunoglobulins (J06)

IVIG	Anthrax immune globulin Rho(D) immune globulin Hepatitis B immune globulin Zoster-immune globulin

Antiserum	Antivenom

Index of bacterial disease

Description	Bacteria classification Growth media

Disease	Gram-positive firmicutes Gram-positive actinobacteria Gram-negative proteobacteria Gram-negative non-proteobacteria Cholera Tuberculosis

Treatment	Antibiotics cell wall nucleic acid mycobacteria protein synthesis other Antibodies Vaccines